objectives primary aim present study evaluate comparative trough effects formoterol salmeterol regulation bronchodilator response regular treatment secondary aim evaluate possible association polymorphism methods sixteen asthmatic subjects mean sd age NUMBER years taking inhaled corticosteroids forced expiratory volume NUMBER s fev1 NUMBER predicted recruited randomised threeway study subjects received treatments NUMBER week washout periods NUMBER formoterol dry powder NUMBER microg twice daily NUMBER salmeterol dry powder NUMBER microg twice daily NUMBER placebo twice daily spirometry lymphocyte parameters measured dose NUMBER h dose treatment domiciliary peak flow treatment results differences density bmax treatments prior dose dose bmax lower active treatments placebo significant salmeterol 12fold geometric mean fold difference NUMBER ci p NUMBER compared placebo n NUMBER NUMBER subjects salmeterol n NUMBER NUMBER formoterol greater NUMBER fall bmax trend analysis polymorphism showed propensity downregulation appeared related occurrence allelic substitution glycine codon NUMBER salmeterol versus NUMBER NUMBER formoterol greater NUMBER fall compared placebo significant differences salmeterol formoterol terms mean individual values downregulation evidence persistent bronchodilator activity active treatments compared placebo significant forced expiratory flow rate NUMBER NUMBER vital capacity mean difference versus salmeterol NUMBER NUMBER ci p NUMBER versus formoterol NUMBER NUMBER ci p NUMBER effects mirrored significant improvements morning peak flow rate compared difference versus salmeterol NUMBER NUMBER ci p NUMBER versus formoterol NUMBER NUMBER ci p NUMBER conclusion differences regular treatment formoterol salmeterol effects lymphocyte regulation end dosing interval drugs exhibiting residual degree bronchodilator activity time point studies evaluate receptor regulation bronchodilator response required susceptible patients homozygous polymorphism beta2 adrenoceptor twice daily beta2 adrenoceptor single blind cross NUMBER week beta2 adrenoceptor beta2 adrenoceptor NUMBER NUMBER fold post hoc NUMBER NUMBER fef25 NUMBER NUMBER NUMBER NUMBER NUMBER placebo mean NUMBER NUMBER NUMBER NUMBER beta2 adrenoceptor NUMBER h glycine NUMBER NUMBER s NUMBER s NUMBER min NUMBER min